<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153112</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-202</org_study_id>
    <secondary_id>2014-000778-20</secondary_id>
    <secondary_id>U1111-1154-9733</secondary_id>
    <nct_id>NCT02153112</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the optimal formulation of the norovirus vaccine from
      different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for
      further development in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like
      particle (VLP) vaccine with aluminum hydroxide. The norovirus vaccine is being tested to
      assess different formulations of the vaccine that will then be further developed. This study
      will look at the number of antibodies to norovirus formed in children, toddlers and infants
      who are administered different formulations of the norovirus vaccine.

      The study enrolled 840 patients. Participants will be randomly assigned (by chance) to one of
      ten treatment groups—which will remain undisclosed to the participant and study doctor during
      the study (unless there is an urgent medical need).

      All participants in Cohort 1 will be vaccinated on Day 1 and Day 29 of the study, and all
      participants in Cohort 2 will be vaccinated on Day 1, Day 56, and Day 112. All treatment
      groups in Cohort 1 will receive either one dose of the norovirus vaccine, or two doses. One
      treatment group in Cohort 2 will receive 2 doses of the norovirus vaccine, and the other
      group will receive 3. In order to keep the treatment undisclosed to the participant and the
      doctor in Cohort 1, those randomized to the one-dose groups will receive the norovirus
      vaccine on Day 1, followed by a dose of placebo vaccine on Day 29. In order to keep the
      treatment arms undisclosed to the participant and the doctor in Cohort 2, those randomized to
      the two-dose groups will receive the norovirus vaccine on Day 1 and Day 56, followed by a
      dose of placebo vaccine on Day 112. Placebo vaccine is saline solution. Participants will be
      asked to record any symptoms that may be related to the vaccine or the injection site in a
      diary card for 7 days after each vaccination.

      This multi-center trial will be conducted in Finland, Panama, and Colombia. The overall time
      to participate in this study is up to 210 days for participants in Cohort 1 and up to 293
      Days for participants in Cohort 2. Participants in Cohort 1 will make 6 visits to the clinic,
      and participants in Cohort 2 will make 10 visits to the clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2015</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1</measure>
    <time_frame>Day 57</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater at Day 57 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 2</measure>
    <time_frame>Day 140</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater at Day 140 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 1</measure>
    <time_frame>Day 1 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 2</measure>
    <time_frame>Day 1 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 3</measure>
    <time_frame>Day 3 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 4</measure>
    <time_frame>Day 4 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 5</measure>
    <time_frame>Day 5 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 6</measure>
    <time_frame>Day 6 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 7</measure>
    <time_frame>Day 7 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination</measure>
    <time_frame>Days 1 through 7 after each vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 4 to &lt;9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to &lt;4 years on the day of vaccination and daily through Day 7 after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature Through Day 7 Following Either Vaccination</measure>
    <time_frame>Post-vaccination approximately 30 minutes and 6 hours later, then daily through Day 7 after each vaccination given on Days 1, 29, 56 or 112</time_frame>
    <description>Body temperature measurement was performed using the thermometer provided by the site through Day 7 after each vaccination. The highest body temperature observed each day was recorded on the Diary Card. Body temperature is categorized as 1) Any (temperature 38°C or higher), 2) 38°C - &lt;38.5°C, 3) 38.5°C - &lt;39°C, 4) 39°C - &lt;39.5°C, 5) 39.5°C - &lt;40°C, 6) 40°C or higher. Number of participants with the particular body temperature is reported within the pre-defined categories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Unsolicited AE Following Either Vaccination Dose</measure>
    <time_frame>Unsolicited AEs were collected within 28 days of all vaccinations (Day 1 to 57 for Cohort 1 and Day 1 to 140 for Cohort 2)</time_frame>
    <description>Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</measure>
    <time_frame>Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293</time_frame>
    <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Norovirus</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 1: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 2a: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Group 3: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 6 months to &lt;1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Group 4: 3 Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/15)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 1: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 3 Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (15/50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 1: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 3 Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/50)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 1: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 3 Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI.1/GII.4 (50/150)</intervention_name>
    <description>Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 1: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 3 Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo saline solution</description>
    <arm_group_label>Cohort 1, Group 1: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 2a: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 1, Group 3: 1 Dose</arm_group_label>
    <arm_group_label>Cohort 2, Group 4: 2 Doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female participants aged between 6 weeks and less than 9 years at the time of
             enrollment.

          2. Are in good health at the time of entry into the trial as determined by medical
             history, physical examination (including vital signs) and clinical judgment of the
             investigator.

          3. Participants legally authorized representative (LAR) signs and dates a written,
             informed consent form (ICF) and any required privacy authorization prior to the
             initiation of any trial procedures, after the nature of the trial has been explained
             according to local regulatory requirements. An assent will also be obtained according
             to age-appropriate country-specific regulations.

          4. Participants who can comply with trial procedures and are available for the duration
             of the trial.

        Exclusion Criteria:

          1. Participants with a clinically significant active infection (as assessed by the
             investigator) or body temperature 38.0°C (100.4°F) or higher within 3 days of the
             intended date of vaccination.

          2. Have received antipyretic/analgesic medications within 24 hours prior to the intended
             vaccine administration.

          3. Known hypersensitivity or allergy to investigational vaccine (including excipients of
             the investigational vaccines).

          4. Participants with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the ability to participate in the
             trial.

          5. Has a history of any progressive or severe neurologic disorder, seizure disorder, or
             neuroinflammatory disease (eg, Guillain-Barré syndrome).

          6. Known or suspected impairment/alteration of immune function, including the following:

               1. Children &lt;18 months of age with history of repeated episodes of acute otitis
                  media (AOM) in the first 6 months of life (AOM defined as a bulging tympanic
                  membrane) and not to be confused with otitis media with effusion (OME).

               2. Chronic use of oral steroids (equivalent to 20 mg/day prednisone for ≥12 weeks/≥2
                  mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1 (use of
                  inhaled, intranasal, or topical corticosteroids is allowed).

               3. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2
                  mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1.

               4. Receipt of immunostimulants within 60 days prior to Day 1.

               5. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation,
                  blood products, and/or plasma derivatives within 3 months prior to Day 1 or
                  planned during the full length of the trial.

               6. Receipt of immunosuppressive therapy within 6 months prior to Day 1.

               7. Human immunodeficiency virus (HIV) infection or HIV-related disease.

               8. Chronic Hepatitis B or C infection.

               9. Heritable immunodeficiency.

          7. Abnormalities of splenic or thymic function.

          8. Has a known bleeding diathesis or any condition that may be associated with a
             prolonged bleeding time.

          9. Has any serious chronic or progressive disease according to judgment of the
             investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic
             disease).

         10. Is participating in any clinical trial with another investigational product 30 days
             prior to first trial visit or intent to participate in another clinical trial at any
             time during the conduct of this trial.

         11. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days
             (for live vaccines) prior to enrollment in this trial.

         12. Are first degree relatives of individuals involved in trial conduct.

         13. Has a history of autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Estudios em Infectologia Pediatrica SAS</name>
      <address>
        <city>Cali</city>
        <state>San Fernando</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoon Rokotetutkimusklinikka</name>
      <address>
        <city>Espoo</city>
        <zip>2230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etela-Helsingin Rokotetutkimusklinikka</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ita-Helsingin Rokotetutkimusklinikka</name>
      <address>
        <city>Helsinki</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaan Rokotetutkimusklinikka</name>
      <address>
        <city>Jarvenpaan</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulun Rokotetutkimusklinikka</name>
      <address>
        <city>Oulu</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porin Rokotetutkimusklinikka</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinajoen Rokotetutkimusklinikka</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun Rokotetutkimusklinikka</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEVAXIN Plaza Carolina - Ciudad de Panama</name>
      <address>
        <city>Ciudad de Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEVAXIN</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Finland</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>December 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2019</results_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02153112/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02153112/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 12 investigative sites in Finland, Panama, and Colombia from 23 June 2015 to 20 June 2018.</recruitment_details>
      <pre_assignment_details>Healthy volunteers (children, toddlers and infants) were enrolled to receive either one, two or three doses of 4 formulation of norovirus GI.1/GII4 bivalent virus like particle (VLP) vaccine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1, Group 1: 1 Dose</title>
          <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1, Group 1: 2 Doses</title>
          <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1, Group 2: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1, Group 2: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 1, Group 2a: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 1, Group 2a: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 1, Group 3: 1 Dose</title>
          <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 1, Group 3: 2 Doses</title>
          <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 2, Group 4: 2 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 2, Group 4: 3 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="60"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="180"/>
                <participants group_id="P10" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="58"/>
                <participants group_id="P9" count="165"/>
                <participants group_id="P10" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per-Protocol Analysis Set (PPS) included all participants who received the planned vaccination and do not have major protocol violations.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1, Group 1: 1 Dose</title>
          <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1, Group 1: 2 Doses</title>
          <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1, Group 2: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1, Group 2: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 1, Group 2a: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 1, Group 2a: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 1, Group 3: 1 Dose</title>
          <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 1, Group 3: 2 Doses</title>
          <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 2, Group 4: 2 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 2, Group 4: 3 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="56"/>
            <count group_id="B7" value="52"/>
            <count group_id="B8" value="56"/>
            <count group_id="B9" value="144"/>
            <count group_id="B10" value="162"/>
            <count group_id="B11" value="742"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B2" value="5.8" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B3" value="2.1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B4" value="2.1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B5" value="1.9" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B6" value="2.1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B7" value="8.3" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="B8" value="7.9" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="B9" value="3.1" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B10" value="3.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="B11" value="4.22" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>EU Registration Age Categories</title>
              <category_list>
                <category>
                  <title>Infants and Toddlers (28 days-23 months)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="56"/>
                    <measurement group_id="B9" value="144"/>
                    <measurement group_id="B10" value="162"/>
                    <measurement group_id="B11" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children (2-11 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="77"/>
                    <measurement group_id="B10" value="72"/>
                    <measurement group_id="B11" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="67"/>
                    <measurement group_id="B10" value="90"/>
                    <measurement group_id="B11" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="56"/>
                    <measurement group_id="B9" value="144"/>
                    <measurement group_id="B10" value="162"/>
                    <measurement group_id="B11" value="627"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="69"/>
                    <measurement group_id="B10" value="75"/>
                    <measurement group_id="B11" value="273"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="24"/>
                    <measurement group_id="B11" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islanders</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiracial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="58"/>
                    <measurement group_id="B10" value="60"/>
                    <measurement group_id="B11" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.4" lower_limit="92" upper_limit="138"/>
                    <measurement group_id="B2" value="116.5" lower_limit="96" upper_limit="138"/>
                    <measurement group_id="B3" value="89.9" lower_limit="67" upper_limit="105"/>
                    <measurement group_id="B4" value="89.8" lower_limit="73" upper_limit="104"/>
                    <measurement group_id="B5" value="89.7" lower_limit="74" upper_limit="117"/>
                    <measurement group_id="B6" value="89.9" lower_limit="72" upper_limit="110"/>
                    <measurement group_id="B7" value="70.6" lower_limit="63" upper_limit="80"/>
                    <measurement group_id="B8" value="69.3" lower_limit="64" upper_limit="75"/>
                    <measurement group_id="B9" value="60.2" lower_limit="50" upper_limit="71"/>
                    <measurement group_id="B10" value="60.2" lower_limit="51" upper_limit="68"/>
                    <measurement group_id="B11" value="85.35" lower_limit="50" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.41" lower_limit="13.7" upper_limit="43.2"/>
                    <measurement group_id="B2" value="22.19" lower_limit="13.6" upper_limit="45.3"/>
                    <measurement group_id="B3" value="13.55" lower_limit="8.0" upper_limit="19.4"/>
                    <measurement group_id="B4" value="13.39" lower_limit="10.0" upper_limit="18.6"/>
                    <measurement group_id="B5" value="13.19" lower_limit="8.8" upper_limit="17.5"/>
                    <measurement group_id="B6" value="13.11" lower_limit="8.9" upper_limit="21.8"/>
                    <measurement group_id="B7" value="9.02" lower_limit="6.0" upper_limit="14.0"/>
                    <measurement group_id="B8" value="8.85" lower_limit="6.2" upper_limit="11.1"/>
                    <measurement group_id="B9" value="6.33" lower_limit="3.5" upper_limit="9.5"/>
                    <measurement group_id="B10" value="6.35" lower_limit="3.4" upper_limit="9.5"/>
                    <measurement group_id="B11" value="12.839" lower_limit="3.4" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1</title>
        <description>Seroresponse was defined as 4-fold rise or greater at Day 57 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 57</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1</title>
          <description>Seroresponse was defined as 4-fold rise or greater at Day 57 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="63.8" upper_limit="87.7"/>
                    <measurement group_id="O2" value="63.5" lower_limit="49.0" upper_limit="76.4"/>
                    <measurement group_id="O3" value="74.5" lower_limit="60.4" upper_limit="85.7"/>
                    <measurement group_id="O4" value="85.7" lower_limit="73.8" upper_limit="93.6"/>
                    <measurement group_id="O5" value="53.2" lower_limit="38.1" upper_limit="67.9"/>
                    <measurement group_id="O6" value="70.4" lower_limit="56.4" upper_limit="82.0"/>
                    <measurement group_id="O7" value="71.4" lower_limit="56.7" upper_limit="83.4"/>
                    <measurement group_id="O8" value="92.7" lower_limit="82.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 2</title>
        <description>Seroresponse was defined as 4-fold rise or greater at Day 140 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 2</title>
          <description>Seroresponse was defined as 4-fold rise or greater at Day 140 in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="48.3" upper_limit="65.9"/>
                    <measurement group_id="O2" value="84.9" lower_limit="78.1" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 1</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 1 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 1</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="66.1"/>
                    <measurement group_id="O3" value="34.4"/>
                    <measurement group_id="O4" value="45.8"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="30.0"/>
                    <measurement group_id="O7" value="11.7"/>
                    <measurement group_id="O8" value="13.3"/>
                    <measurement group_id="O9" value="22.2"/>
                    <measurement group_id="O10" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="66.1"/>
                    <measurement group_id="O3" value="34.4"/>
                    <measurement group_id="O4" value="35.6"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="8.3"/>
                    <measurement group_id="O8" value="13.3"/>
                    <measurement group_id="O9" value="22.2"/>
                    <measurement group_id="O10" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="3.3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1.1"/>
                    <measurement group_id="O10" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 2</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 1 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 2</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="44.1"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="25.4"/>
                    <measurement group_id="O5" value="13.3"/>
                    <measurement group_id="O6" value="15.0"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="5.0"/>
                    <measurement group_id="O9" value="13.3"/>
                    <measurement group_id="O10" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="6.6"/>
                    <measurement group_id="O4" value="23.7"/>
                    <measurement group_id="O5" value="13.3"/>
                    <measurement group_id="O6" value="13.3"/>
                    <measurement group_id="O7" value="6.9"/>
                    <measurement group_id="O8" value="5.1"/>
                    <measurement group_id="O9" value="13.6"/>
                    <measurement group_id="O10" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 3</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 3 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 3</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="20.3"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="10.0"/>
                    <measurement group_id="O7" value="5.0"/>
                    <measurement group_id="O8" value="6.7"/>
                    <measurement group_id="O9" value="2.2"/>
                    <measurement group_id="O10" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="15.5"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="20.3"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="3.4"/>
                    <measurement group_id="O8" value="6.8"/>
                    <measurement group_id="O9" value="2.3"/>
                    <measurement group_id="O10" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 4</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 4 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 4</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="11.9"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="10.0"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="6.7"/>
                    <measurement group_id="O9" value="3.3"/>
                    <measurement group_id="O10" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11.9"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="6.7"/>
                    <measurement group_id="O7" value="5.2"/>
                    <measurement group_id="O8" value="6.8"/>
                    <measurement group_id="O9" value="3.4"/>
                    <measurement group_id="O10" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 5</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 5 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 5</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="3.3"/>
                    <measurement group_id="O8" value="8.3"/>
                    <measurement group_id="O9" value="1.7"/>
                    <measurement group_id="O10" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="3.4"/>
                    <measurement group_id="O8" value="8.5"/>
                    <measurement group_id="O9" value="1.7"/>
                    <measurement group_id="O10" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 6</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 6 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 6</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="5.0"/>
                    <measurement group_id="O9" value="1.1"/>
                    <measurement group_id="O10" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="5.1"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1.7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 7</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
        <time_frame>Day 7 after either of the vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination on Day 7</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occur on the vaccination day through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine). Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="176"/>
                <count group_id="O10" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="3.3"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.7"/>
                    <measurement group_id="O5" value="1.7"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="1.7"/>
                    <measurement group_id="O8" value="3.4"/>
                    <measurement group_id="O9" value="0.6"/>
                    <measurement group_id="O10" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination</title>
        <description>Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 4 to &lt;9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to &lt;4 years on the day of vaccination and daily through Day 7 after each vaccination.</description>
        <time_frame>Days 1 through 7 after each vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination</title>
          <description>Systemic AEs are defined as headache, fatigue, myalgia, arthralgia, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 4 to &lt;9 years; and irritability/fussiness, drowsiness, loss of appetite, vomiting (number per day/intensity), and diarrhea (number per day/consistency) for children aged 6 weeks to &lt;4 years on the day of vaccination and daily through Day 7 after each vaccination.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="61.0"/>
                    <measurement group_id="O3" value="44.3"/>
                    <measurement group_id="O4" value="54.2"/>
                    <measurement group_id="O5" value="41.7"/>
                    <measurement group_id="O6" value="43.3"/>
                    <measurement group_id="O7" value="56.7"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="60.0"/>
                    <measurement group_id="O10" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="6.6"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="11.7"/>
                    <measurement group_id="O7" value="27.6"/>
                    <measurement group_id="O8" value="16.9"/>
                    <measurement group_id="O9" value="21.6"/>
                    <measurement group_id="O10" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="13.1"/>
                    <measurement group_id="O4" value="23.7"/>
                    <measurement group_id="O5" value="18.3"/>
                    <measurement group_id="O6" value="18.3"/>
                    <measurement group_id="O7" value="31.0"/>
                    <measurement group_id="O8" value="25.4"/>
                    <measurement group_id="O9" value="31.8"/>
                    <measurement group_id="O10" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/Fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23.0"/>
                    <measurement group_id="O4" value="30.5"/>
                    <measurement group_id="O5" value="23.3"/>
                    <measurement group_id="O6" value="18.3"/>
                    <measurement group_id="O7" value="27.6"/>
                    <measurement group_id="O8" value="23.7"/>
                    <measurement group_id="O9" value="40.3"/>
                    <measurement group_id="O10" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.4"/>
                    <measurement group_id="O4" value="22.0"/>
                    <measurement group_id="O5" value="23.3"/>
                    <measurement group_id="O6" value="21.7"/>
                    <measurement group_id="O7" value="22.4"/>
                    <measurement group_id="O8" value="20.3"/>
                    <measurement group_id="O9" value="33.5"/>
                    <measurement group_id="O10" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="33.9"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="18.3"/>
                    <measurement group_id="O7" value="25.9"/>
                    <measurement group_id="O8" value="23.7"/>
                    <measurement group_id="O9" value="22.7"/>
                    <measurement group_id="O10" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Temperature Through Day 7 Following Either Vaccination</title>
        <description>Body temperature measurement was performed using the thermometer provided by the site through Day 7 after each vaccination. The highest body temperature observed each day was recorded on the Diary Card. Body temperature is categorized as 1) Any (temperature 38°C or higher), 2) 38°C - &lt;38.5°C, 3) 38.5°C - &lt;39°C, 4) 39°C - &lt;39.5°C, 5) 39.5°C - &lt;40°C, 6) 40°C or higher. Number of participants with the particular body temperature is reported within the pre-defined categories.</description>
        <time_frame>Post-vaccination approximately 30 minutes and 6 hours later, then daily through Day 7 after each vaccination given on Days 1, 29, 56 or 112</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature Through Day 7 Following Either Vaccination</title>
          <description>Body temperature measurement was performed using the thermometer provided by the site through Day 7 after each vaccination. The highest body temperature observed each day was recorded on the Diary Card. Body temperature is categorized as 1) Any (temperature 38°C or higher), 2) 38°C - &lt;38.5°C, 3) 38.5°C - &lt;39°C, 4) 39°C - &lt;39.5°C, 5) 39.5°C - &lt;40°C, 6) 40°C or higher. Number of participants with the particular body temperature is reported within the pre-defined categories.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any (temperature 38°C or higher)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="26"/>
                    <measurement group_id="O10" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>38°C - &lt;38.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>38.5°C - &lt;39°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39°C - &lt;39.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39.5°C - &lt;40°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40°C or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Unsolicited AE Following Either Vaccination Dose</title>
        <description>Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited.</description>
        <time_frame>Unsolicited AEs were collected within 28 days of all vaccinations (Day 1 to 57 for Cohort 1 and Day 1 to 140 for Cohort 2)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Unsolicited AE Following Either Vaccination Dose</title>
          <description>Unsolicited AEs are any local or systemic AEs, as defined by this study, that are not solicited.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7"/>
                    <measurement group_id="O2" value="55.9"/>
                    <measurement group_id="O3" value="67.2"/>
                    <measurement group_id="O4" value="69.5"/>
                    <measurement group_id="O5" value="55.0"/>
                    <measurement group_id="O6" value="46.7"/>
                    <measurement group_id="O7" value="73.3"/>
                    <measurement group_id="O8" value="70.0"/>
                    <measurement group_id="O9" value="77.2"/>
                    <measurement group_id="O10" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="1.7"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="8.3"/>
                    <measurement group_id="O9" value="9.4"/>
                    <measurement group_id="O10" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)</title>
        <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Here, overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse for GI.1 Virus-Like Particle (VLP) (Pan-Ig ELISA)</title>
          <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Here, overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="138"/>
                <count group_id="O10" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="77.0" upper_limit="95.7"/>
                    <measurement group_id="O2" value="82.7" lower_limit="69.7" upper_limit="91.8"/>
                    <measurement group_id="O3" value="92.2" lower_limit="81.1" upper_limit="97.8"/>
                    <measurement group_id="O4" value="92.9" lower_limit="82.7" upper_limit="98.0"/>
                    <measurement group_id="O5" value="78.7" lower_limit="64.3" upper_limit="89.3"/>
                    <measurement group_id="O6" value="94.4" lower_limit="84.6" upper_limit="98.8"/>
                    <measurement group_id="O7" value="95.9" lower_limit="86.0" upper_limit="99.5"/>
                    <measurement group_id="O8" value="100.0" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O9" value="94.9" lower_limit="89.8" upper_limit="97.9"/>
                    <measurement group_id="O10" value="98.0" lower_limit="94.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)</title>
        <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse for GII.4 Virus-Like Particle (VLP) (Pan-Ig ELISA)</title>
          <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="134"/>
                <count group_id="O10" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="68.0" upper_limit="90.6"/>
                    <measurement group_id="O2" value="69.2" lower_limit="54.9" upper_limit="81.3"/>
                    <measurement group_id="O3" value="76.5" lower_limit="62.5" upper_limit="87.2"/>
                    <measurement group_id="O4" value="87.5" lower_limit="75.9" upper_limit="94.8"/>
                    <measurement group_id="O5" value="63.8" lower_limit="48.5" upper_limit="77.3"/>
                    <measurement group_id="O6" value="72.2" lower_limit="58.4" upper_limit="83.5"/>
                    <measurement group_id="O7" value="75.5" lower_limit="61.1" upper_limit="86.7"/>
                    <measurement group_id="O8" value="92.7" lower_limit="82.4" upper_limit="98.0"/>
                    <measurement group_id="O9" value="58.2" lower_limit="49.4" upper_limit="66.7"/>
                    <measurement group_id="O10" value="86.0" lower_limit="79.4" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="144"/>
                <count group_id="O10" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6039.1" lower_limit="4786.3" upper_limit="7619.9"/>
                    <measurement group_id="O2" value="12907.6" lower_limit="10875.5" upper_limit="15319.4"/>
                    <measurement group_id="O3" value="2856.2" lower_limit="2232.0" upper_limit="3654.9"/>
                    <measurement group_id="O4" value="7350.8" lower_limit="6208.6" upper_limit="8703.2"/>
                    <measurement group_id="O5" value="3892.1" lower_limit="2852.7" upper_limit="5310.3"/>
                    <measurement group_id="O6" value="12623.8" lower_limit="10074.0" upper_limit="15818.9"/>
                    <measurement group_id="O7" value="1240.1" lower_limit="948.3" upper_limit="1621.7"/>
                    <measurement group_id="O8" value="7139.1" lower_limit="5863.5" upper_limit="8692.2"/>
                    <measurement group_id="O9" value="4121.1" lower_limit="3688.4" upper_limit="4604.6"/>
                    <measurement group_id="O10" value="11806.3" lower_limit="10537.6" upper_limit="13227.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="143"/>
                <count group_id="O10" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11057.9" lower_limit="8257.3" upper_limit="14808.3"/>
                    <measurement group_id="O2" value="10228.3" lower_limit="8171.2" upper_limit="12803.3"/>
                    <measurement group_id="O3" value="3293.0" lower_limit="2220.5" upper_limit="4883.3"/>
                    <measurement group_id="O4" value="7955.2" lower_limit="6065.9" upper_limit="10433.0"/>
                    <measurement group_id="O5" value="5950.6" lower_limit="3927.2" upper_limit="9016.7"/>
                    <measurement group_id="O6" value="10896.5" lower_limit="8452.0" upper_limit="14048.0"/>
                    <measurement group_id="O7" value="620.2" lower_limit="383.7" upper_limit="1002.7"/>
                    <measurement group_id="O8" value="3252.1" lower_limit="2403.3" upper_limit="4400.7"/>
                    <measurement group_id="O9" value="1316.2" lower_limit="1103.9" upper_limit="1569.4"/>
                    <measurement group_id="O10" value="3829.8" lower_limit="3311.7" upper_limit="4428.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="138"/>
                <count group_id="O10" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.22" lower_limit="12.98" upper_limit="28.44"/>
                    <measurement group_id="O2" value="43.55" lower_limit="25.21" upper_limit="75.25"/>
                    <measurement group_id="O3" value="44.11" lower_limit="28.48" upper_limit="68.32"/>
                    <measurement group_id="O4" value="89.95" lower_limit="56.51" upper_limit="143.18"/>
                    <measurement group_id="O5" value="13.01" lower_limit="7.92" upper_limit="21.37"/>
                    <measurement group_id="O6" value="43.99" lower_limit="27.71" upper_limit="69.83"/>
                    <measurement group_id="O7" value="47.45" lower_limit="30.59" upper_limit="73.60"/>
                    <measurement group_id="O8" value="276.41" lower_limit="206.44" upper_limit="370.09"/>
                    <measurement group_id="O9" value="34.11" lower_limit="26.54" upper_limit="43.84"/>
                    <measurement group_id="O10" value="122.80" lower_limit="93.93" upper_limit="160.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="49"/>
                <count group_id="O8" value="55"/>
                <count group_id="O9" value="134"/>
                <count group_id="O10" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" lower_limit="5.63" upper_limit="9.87"/>
                    <measurement group_id="O2" value="10.00" lower_limit="6.74" upper_limit="14.85"/>
                    <measurement group_id="O3" value="10.87" lower_limit="7.48" upper_limit="15.77"/>
                    <measurement group_id="O4" value="19.20" lower_limit="12.66" upper_limit="29.11"/>
                    <measurement group_id="O5" value="5.62" lower_limit="3.83" upper_limit="8.22"/>
                    <measurement group_id="O6" value="11.93" lower_limit="7.46" upper_limit="19.07"/>
                    <measurement group_id="O7" value="9.54" lower_limit="5.80" upper_limit="15.71"/>
                    <measurement group_id="O8" value="55.73" lower_limit="36.50" upper_limit="85.09"/>
                    <measurement group_id="O9" value="7.85" lower_limit="5.86" upper_limit="10.50"/>
                    <measurement group_id="O10" value="23.55" lower_limit="17.85" upper_limit="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)</title>
        <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP (HBGA)</title>
          <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="41"/>
                <count group_id="O9" value="129"/>
                <count group_id="O10" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="60.4" upper_limit="86.4"/>
                    <measurement group_id="O2" value="91.5" lower_limit="79.6" upper_limit="97.6"/>
                    <measurement group_id="O3" value="50.0" lower_limit="34.6" upper_limit="65.4"/>
                    <measurement group_id="O4" value="95.9" lower_limit="86.0" upper_limit="99.5"/>
                    <measurement group_id="O5" value="51.2" lower_limit="35.5" upper_limit="66.7"/>
                    <measurement group_id="O6" value="89.4" lower_limit="76.9" upper_limit="96.5"/>
                    <measurement group_id="O7" value="36.7" lower_limit="19.9" upper_limit="56.1"/>
                    <measurement group_id="O8" value="85.4" lower_limit="70.8" upper_limit="94.4"/>
                    <measurement group_id="O9" value="48.1" lower_limit="39.2" upper_limit="57.0"/>
                    <measurement group_id="O10" value="67.4" lower_limit="59.1" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" lower_limit="84.1" upper_limit="98.8"/>
                    <measurement group_id="O2" value="98.0" lower_limit="89.4" upper_limit="99.9"/>
                    <measurement group_id="O3" value="81.6" lower_limit="68.0" upper_limit="91.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="93.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="74.4" lower_limit="58.8" upper_limit="86.5"/>
                    <measurement group_id="O6" value="98.0" lower_limit="89.4" upper_limit="99.9"/>
                    <measurement group_id="O7" value="50.0" lower_limit="33.8" upper_limit="66.2"/>
                    <measurement group_id="O8" value="96.0" lower_limit="86.3" upper_limit="99.5"/>
                    <measurement group_id="O9" value="92.0" lower_limit="86.1" upper_limit="95.9"/>
                    <measurement group_id="O10" value="94.9" lower_limit="90.2" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="134"/>
                <count group_id="O10" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="68.0" upper_limit="91.2"/>
                    <measurement group_id="O2" value="93.8" lower_limit="82.8" upper_limit="98.7"/>
                    <measurement group_id="O3" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O4" value="95.9" lower_limit="86.0" upper_limit="99.5"/>
                    <measurement group_id="O5" value="68.1" lower_limit="52.9" upper_limit="80.9"/>
                    <measurement group_id="O6" value="90.2" lower_limit="78.6" upper_limit="96.7"/>
                    <measurement group_id="O7" value="47.4" lower_limit="31.0" upper_limit="64.2"/>
                    <measurement group_id="O8" value="87.0" lower_limit="73.7" upper_limit="95.1"/>
                    <measurement group_id="O9" value="48.5" lower_limit="39.8" upper_limit="57.3"/>
                    <measurement group_id="O10" value="70.7" lower_limit="62.7" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="142"/>
                <count group_id="O10" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.4" lower_limit="136.0" upper_limit="203.6"/>
                    <measurement group_id="O2" value="491.4" lower_limit="397.1" upper_limit="608.1"/>
                    <measurement group_id="O3" value="135.2" lower_limit="106.5" upper_limit="171.7"/>
                    <measurement group_id="O4" value="346.0" lower_limit="297.5" upper_limit="402.3"/>
                    <measurement group_id="O5" value="145.0" lower_limit="108.6" upper_limit="193.8"/>
                    <measurement group_id="O6" value="531.1" lower_limit="424.0" upper_limit="665.2"/>
                    <measurement group_id="O7" value="63.1" lower_limit="45.3" upper_limit="87.9"/>
                    <measurement group_id="O8" value="350.1" lower_limit="273.7" upper_limit="447.9"/>
                    <measurement group_id="O9" value="202.2" lower_limit="180.7" upper_limit="226.2"/>
                    <measurement group_id="O10" value="561.7" lower_limit="499.2" upper_limit="632.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="51"/>
                <count group_id="O9" value="136"/>
                <count group_id="O10" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="982.1" lower_limit="652.4" upper_limit="1478.4"/>
                    <measurement group_id="O2" value="933.6" lower_limit="678.3" upper_limit="1284.9"/>
                    <measurement group_id="O3" value="197.1" lower_limit="119.0" upper_limit="326.5"/>
                    <measurement group_id="O4" value="514.8" lower_limit="372.1" upper_limit="712.3"/>
                    <measurement group_id="O5" value="444.6" lower_limit="261.9" upper_limit="754.8"/>
                    <measurement group_id="O6" value="721.8" lower_limit="510.2" upper_limit="1021.1"/>
                    <measurement group_id="O7" value="68.5" lower_limit="44.1" upper_limit="106.4"/>
                    <measurement group_id="O8" value="282.6" lower_limit="194.8" upper_limit="410.0"/>
                    <measurement group_id="O9" value="102.4" lower_limit="83.1" upper_limit="126.1"/>
                    <measurement group_id="O10" value="243.9" lower_limit="203.3" upper_limit="292.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="137"/>
                <count group_id="O10" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.93" lower_limit="7.58" upper_limit="10.53"/>
                    <measurement group_id="O2" value="23.07" lower_limit="18.56" upper_limit="28.68"/>
                    <measurement group_id="O3" value="7.22" lower_limit="5.47" upper_limit="9.52"/>
                    <measurement group_id="O4" value="22.15" lower_limit="19.06" upper_limit="25.73"/>
                    <measurement group_id="O5" value="6.10" lower_limit="4.41" upper_limit="8.42"/>
                    <measurement group_id="O6" value="24.21" lower_limit="19.36" upper_limit="30.29"/>
                    <measurement group_id="O7" value="3.68" lower_limit="2.64" upper_limit="5.13"/>
                    <measurement group_id="O8" value="20.01" lower_limit="15.54" upper_limit="25.76"/>
                    <measurement group_id="O9" value="11.48" lower_limit="10.09" upper_limit="13.06"/>
                    <measurement group_id="O10" value="32.03" lower_limit="27.38" upper_limit="37.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Cohort 1: Day 57; Cohort 2: Day 140</time_frame>
        <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>Per-protocol set included all participants who received the planned vaccination and do not have major protocol violations. Overall number of participants analyzed is the number of participants with data available at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="46"/>
                <count group_id="O9" value="134"/>
                <count group_id="O10" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" lower_limit="6.93" upper_limit="12.52"/>
                    <measurement group_id="O2" value="12.73" lower_limit="9.60" upper_limit="16.90"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.94" upper_limit="7.28"/>
                    <measurement group_id="O4" value="15.95" lower_limit="12.31" upper_limit="20.66"/>
                    <measurement group_id="O5" value="8.34" lower_limit="5.01" upper_limit="13.87"/>
                    <measurement group_id="O6" value="15.36" lower_limit="11.26" upper_limit="20.96"/>
                    <measurement group_id="O7" value="3.91" lower_limit="2.60" upper_limit="5.88"/>
                    <measurement group_id="O8" value="17.00" lower_limit="11.66" upper_limit="24.80"/>
                    <measurement group_id="O9" value="3.73" lower_limit="2.84" upper_limit="4.90"/>
                    <measurement group_id="O10" value="8.13" lower_limit="6.39" upper_limit="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</title>
        <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
        <time_frame>Cohort 1: Day 1 up to Day 210; Cohort 2: Day 1 up to Day 293</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1, Group 1: 1 Dose</title>
            <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1, Group 1: 2 Doses</title>
            <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1, Group 2: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1, Group 2: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1, Group 2a: 1 Dose</title>
            <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1, Group 2a: 2 Doses</title>
            <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 1, Group 3: 1 Dose</title>
            <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 1, Group 3: 2 Doses</title>
            <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2, Group 4: 2 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 2, Group 4: 3 Doses</title>
            <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</title>
          <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of vaccine (NoV GI.1/GII.4 bivalent VLP vaccine or control vaccine).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="60"/>
                <count group_id="O8" value="60"/>
                <count group_id="O9" value="180"/>
                <count group_id="O10" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited AEs 28 days after each vaccination and Serious Adverse Events (SAEs) and AEs leading to trial withdrawal throughout the trial (Up to Day 210 for Cohort 1 and Day 293 for Cohort 2)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1, Group 1: 1 Dose</title>
          <description>Children 4 to &lt;9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1, Group 1: 2 Doses</title>
          <description>Children 4 to &lt;9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1, Group 2: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1, Group 2: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 1, Group 2a: 1 Dose</title>
          <description>Children 1 to &lt;4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 1, Group 2a: 2 Doses</title>
          <description>Children 1 to &lt;4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 1, Group 3: 1 Dose</title>
          <description>Toddlers 6 months to &lt;1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 1, Group 3: 2 Doses</title>
          <description>Toddlers 6 months to &lt;1 year of age received 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 2, Group 4: 2 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 2, Group 4: 3 Doses</title>
          <description>Infants 6 weeks to &lt;6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="24" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Incarcerated Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Muscle Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia Respiratory Syncytial Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns Third Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular Torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="119" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="122" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="86" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="92" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

